Jana Zuchnicka
Ostrava, MO, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.
Journal: Annals of hematology
Published: August 10, 2025
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic.
Journal: Cancer medicine
Published: October 07, 2024
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
Journal: HemaSphere
Published: May 14, 2024
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Journal: EClinicalMedicine
Published: July 31, 2023
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Journal: British journal of haematology
Published: December 29, 2022
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Journal: Annals of hematology
Published: April 11, 2022
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Journal: British journal of haematology
Published: December 23, 2020
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
Journal: British journal of haematology
Published: July 16, 2020
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Journal: Hematological oncology
Published: February 01, 2020
Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study.
Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
Published: May 09, 2019
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Journal: American journal of hematology
Published: October 17, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026